BioStock: BioInvent expects data from seven clinical studies in 2024

BioInvent entered 2024 with a solid financial reserve of 1358 SEK million, equivalent to 132 million USD. Anticipating significant milestones, the company is poised to release data from seven clinical studies throughout the year. Thus building on the momentum generated in 2023 with progress across six clinical programmes.  

Read the article at biostock.se:

https://www.biostock.se/en/2024/01/bioinvent-expects-data-from-seven-clinical-studies-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/